LIVIVO - Search results -

Search results

Result 1 - 10 of total 11

Search options

Article: [Cutaneous melanoma; diagnostic procedures and their evaluation in diagnosing and mapping sentinel nodes. Part 2].

Valsamaki, Pipitsa / Zanglis, Antonios / Chatzipetrou, Alexia

2010 Volume 13, Issue 2, Page(s) 191–196

Abstract: The second part of this review describes the advantages, and evaluates the radionuclide-guided methods for sentinel lymph node localization and also evaluates the intraoperative application of the blue dye technique in melanoma. By combining the two ... ...

Abstract	The second part of this review describes the advantages, and evaluates the radionuclide-guided methods for sentinel lymph node localization and also evaluates the intraoperative application of the blue dye technique in melanoma. By combining the two techniques, the detection rate rises to 96%-98%. The presence of cancer cells in the sentinel node is histopathologically shown by using hematoxylin-eosin and by using sensitive techniques for the detection of micrometastases. Immunohistochemical tech-niques specific for epithelial markers and polymerase chain reaction examination are also applied. Sentinel lymph node biopsy suggests whether regional elective lymphade-nectomy shall be performed.
MeSH term(s)	Lymphatic Metastasis ; Melanoma/diagnosis ; Melanoma/pathology ; Sentinel Lymph Node Biopsy/methods ; Skin Neoplasms/diagnosis ; Skin Neoplasms/pathology
Language	Greek
Publishing date	2010-05
Publishing country	Greece
Document type	English Abstract ; Journal Article ; Review
ZDB-ID	2186026-9
ISSN	1790-5427 ; 1108-1430
ISSN	1790-5427 ; 1108-1430
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6058: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article: Bactericidal/permeability-increasing protein antineutrophil cytoplasmic antibodies (ANCA) and associated diseases: clinical relevance of an emerging ANCA target antigen.

Emmi, Lorenzo / Chatzipetrou, Alexia

Annali italiani di medicina interna : organo ufficiale della Societa italiana di medicina interna

2005 Volume 20, Issue 4, Page(s) 205–208

MeSH term(s)	Antibodies, Antineutrophil Cytoplasmic/immunology ; Antimicrobial Cationic Peptides ; Blood Proteins/immunology ; Cystic Fibrosis/immunology ; Humans ; Inflammatory Bowel Diseases/immunology ; Membrane Proteins/immunology ; Vasculitis/immunology
Chemical Substances	Antibodies, Antineutrophil Cytoplasmic ; Antimicrobial Cationic Peptides ; Blood Proteins ; Membrane Proteins ; bactericidal permeability increasing protein
Language	English
Publishing date	2005-10
Publishing country	Italy
Document type	Comment ; Editorial
ZDB-ID	639182-5
ISSN	0393-9340 ; 1122-0538
ISSN	0393-9340 ; 1122-0538
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.B 3112: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Biologicals in atopic disease in pregnancy: An EAACI position paper.

Pfaller, Birgit / José Yepes-Nuñez, Juan / Agache, Ioana / Akdis, Cezmi A / Alsalamah, Mohammad / Bavbek, Sevim / Bossios, Apostolos / Boyman, Onur / Chaker, Adam / Chan, Susan / Chatzipetrou, Alexia / du Toit, George / Jutel, Marek / Kauppi, Paula / Kolios, Antonios / Li, Carmen / Matucci, Andrea / Marson, Alanna / Bendien, Sarah /

Palomares, Oscar / Rogala, Barbara / Szepfalusi, Zsolt / Untersmayr, Eva / Vultaggio, Alessandra / Eiwegger, Thomas

Allergy

2020 Volume 76, Issue 1, Page(s) 71–89

Abstract: Biologicals have transformed the management of severe disease phenotypes in asthma, atopic dermatitis, and chronic spontaneous urticaria. As a result, the number of approved biologicals for the treatment of atopic diseases is continuously increasing. ... ...

Abstract	Biologicals have transformed the management of severe disease phenotypes in asthma, atopic dermatitis, and chronic spontaneous urticaria. As a result, the number of approved biologicals for the treatment of atopic diseases is continuously increasing. Although atopic diseases are among the most common diseases in the reproductive age, investigations, and information on half-life, pharmacokinetics defining the neonatal Fc receptors (FcRn) and most important safety of biologicals in pregnancy are lacking. Given the complex sequence of immunological events that regulate conception, fetal development, and the intrauterine and postnatal maturation of the immune system, this information is of utmost importance. We conducted a systematic review on biologicals in pregnancy for indications of atopic diseases. Evidence in this field is scarce and mainly reserved to reports on the usage of omalizumab. This lack of evidence demands the establishment of a multidisciplinary approach for the management of pregnant women who receive biologicals and multicenter registries for long-term follow-up, drug trial designs suitable for women in the reproductive age, and better experimental models that represent the human situation. Due to the very long half-life of biologicals, preconception counseling and healthcare provider education are crucial to offer the best care for mother and fetus. This position paper integrates available data on safety of biologicals during pregnancy in atopic diseases via a systematic review with a detailed review on immunological considerations how inhibition of different pathways may impact pregnancy.
MeSH term(s)	Asthma/drug therapy ; Asthma/epidemiology ; Biological Factors ; Biological Products/therapeutic use ; Dermatitis, Atopic/drug therapy ; Dermatitis, Atopic/epidemiology ; Female ; Humans ; Infant, Newborn ; Multicenter Studies as Topic ; Omalizumab ; Pregnancy
Chemical Substances	Biological Factors ; Biological Products ; Omalizumab (2P471X1Z11)
Language	English
Publishing date	2020-03-18
Publishing country	Denmark
Document type	Journal Article ; Systematic Review
ZDB-ID	391933-x
ISSN	1398-9995 ; 0105-4538
ISSN (online)	1398-9995
ISSN	0105-4538
DOI	10.1111/all.14282
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Uh III Zs.150: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MO 125: Show issues

Order via subito

Details ▾

Article ; Online: Considerations on biologicals for patients with allergic disease in times of the COVID-19 pandemic: An EAACI statement.

Vultaggio, Alessandra / Agache, Ioana / Akdis, Cezmi A / Akdis, Mubeccel / Bavbek, Sevim / Bossios, Apostolos / Bousquet, Jean / Boyman, Onur / Chaker, Adam M / Chan, Susan / Chatzipetrou, Alexia / Feleszko, Wojciech / Firinu, Davide / Jutel, Marek / Kauppi, Paula / Klimek, Ludger / Kolios, Antonios / Kothari, Akash / Kowalski, Marek L /

Matucci, Andrea / Palomares, Oscar / Pfaar, Oliver / Rogala, Barbara / Untersmayr, Eva / Eiwegger, Thomas

Allergy

2020 Volume 75, Issue 11, Page(s) 2764–2774

Abstract: The outbreak of the SARS-CoV-2-induced coronavirus disease 2019 (COVID-19) pandemic re-shaped doctor-patient interaction and challenged capacities of healthcare systems. It created many issues around the optimal and safest way to treat complex patients ... ...

Abstract	The outbreak of the SARS-CoV-2-induced coronavirus disease 2019 (COVID-19) pandemic re-shaped doctor-patient interaction and challenged capacities of healthcare systems. It created many issues around the optimal and safest way to treat complex patients with severe allergic disease. A significant number of the patients are on treatment with biologicals, and clinicians face the challenge to provide optimal care during the pandemic. Uncertainty of the potential risks for these patients is related to the fact that the exact sequence of immunological events during SARS-CoV-2 is not known. Severe COVID-19 patients may experience a "cytokine storm" and associated organ damage characterized by an exaggerated release of pro-inflammatory type 1 and type 3 cytokines. These inflammatory responses are potentially counteracted by anti-inflammatory cytokines and type 2 responses. This expert-based EAACI statement aims to provide guidance on the application of biologicals targeting type 2 inflammation in patients with allergic disease. Currently, there is very little evidence for an enhanced risk of patients with allergic diseases to develop severe COVID-19. Studies focusing on severe allergic phenotypes are lacking. At present, noninfected patients on biologicals for the treatment of asthma, atopic dermatitis, chronic rhinosinusitis with nasal polyps, or chronic spontaneous urticaria should continue their biologicals targeting type 2 inflammation via self-application. In case of an active SARS-CoV-2 infection, biological treatment needs to be stopped until clinical recovery and SARS-CoV-2 negativity is established and treatment with biologicals should be re-initiated. Maintenance of add-on therapy and a constant assessment of disease control, apart from acute management, are demanded.
MeSH term(s)	Academies and Institutes ; Biological Products/immunology ; Biological Products/therapeutic use ; COVID-19/complications ; COVID-19/immunology ; Europe ; Humans ; Hypersensitivity/complications ; Hypersensitivity/drug therapy ; Hypersensitivity/immunology ; Pandemics
Chemical Substances	Biological Products
Keywords	covid19
Language	English
Publishing date	2020-06-05
Publishing country	Denmark
Document type	Journal Article ; Practice Guideline
ZDB-ID	391933-x
ISSN	1398-9995 ; 0105-4538
ISSN (online)	1398-9995
ISSN	0105-4538
DOI	10.1111/all.14407
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Uh III Zs.150: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MO 125: Show issues

Order via subito

Details ▾

Article: Considerations on biologicals for patients with allergic disease in times of the COVID-19 pandemic: An EAACI statement

Matucci, Andrea / Palomares, Oscar / Pfaar, Oliver / Rogala, Barbara / Untersmayr, Eva / Eiwegger, Thomas

Allergy

Abstract	The outbreak of the SARS-CoV-2-induced coronavirus disease 2019 (COVID-19) pandemic re-shaped doctor-patient interaction and challenged capacities of healthcare systems. It created many issues around the optimal and safest way to treat complex patients with severe allergic disease. A significant number of the patients are on treatment with biologicals, and clinicians face the challenge to provide optimal care during the pandemic. Uncertainty of the potential risks for these patients is related to the fact that the exact sequence of immunological events during SARS-CoV-2 is not known. Severe COVID-19 patients may experience a "cytokine storm" and associated organ damage characterized by an exaggerated release of pro-inflammatory type 1 and type 3 cytokines. These inflammatory responses are potentially counteracted by anti-inflammatory cytokines and type 2 responses. This expert-based EAACI statement aims to provide guidance on the application of biologicals targeting type 2 inflammation in patients with allergic disease. Currently, there is very little evidence for an enhanced risk of patients with allergic diseases to develop severe COVID-19. Studies focusing on severe allergic phenotypes are lacking. At present, noninfected patients on biologicals for the treatment of asthma, atopic dermatitis, chronic rhinosinusitis with nasal polyps, or chronic spontaneous urticaria should continue their biologicals targeting type 2 inflammation via self-application. In case of an active SARS-CoV-2 infection, biological treatment needs to be stopped until clinical recovery and SARS-CoV-2 negativity is established and treatment with biologicals should be re-initiated. Maintenance of add-on therapy and a constant assessment of disease control, apart from acute management, are demanded.
Keywords	covid19
Publisher	WHO
Document type	Article
Note	WHO #Covidence: #543161
Database	COVID19

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾

Article ; Online: Considerations on Biologicals for Patients with allergic disease in times of the COVID‐19 pandemic

Vultaggio, Alessandra / Agache, Ioana / Akdis, Cezmi A. / Akdis, Mubeccel / Bavbek, Sevim / Bossios, Apostolos / Bousquet, Jean / Boyman, Onur / Chaker, Adam M. / Chan, Susan / Chatzipetrou, Alexia / Feleszko, Wojciech / Firinu, Davide / Jutel, Marek / Kauppi, Paula / Klimek, Ludger / Kolios, Antonios / Kothari, Akash / Kowalski, Marek L. /

Matucci, Andrea / Palomares, Oscar / Pfaar, Oliver / Rogala, Barbara / Untersmayr, Eva / Eiwegger, Thomas

Allergy ; ISSN 0105-4538 1398-9995

an EAACI Statement

2020

Keywords	Immunology ; Immunology and Allergy ; covid19
Language	English
Publisher	Wiley
Publishing country	us
Document type	Article ; Online
DOI	10.1111/all.14407
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article: Use of biologicals in allergic and type-2 inflammatory diseases during the current COVID-19 pandemic: Position paper of Ärzteverband Deutscher Allergologen (AeDA)A, Deutsche Gesellschaft für Allergologie und Klinische Immunologie (DGAKI)B, Gesellschaft für Pädiatrische Allergologie und Umweltmedizin (GPA)C, Österreichische Gesellschaft für Allergologie und Immunologie (ÖGAI)D, Luxemburgische Gesellschaft für Allergologie und Immunologie (LGAI)E, Österreichische Gesellschaft für Pneumologie (ÖGP)F in co-operation with the German, Austrian, and Swiss ARIA groupsG, and the European Academy of Allergy and Clinical Immunology (EAACI)H

Klimek, Ludger / Pfaar, Oliver / Worm, Margitta / Eiwegger, Thomas / Hagemann, Jan / Ollert, Markus / Untersmayr, Eva / Hoffmann-Sommergruber, Karin / Vultaggio, Alessandra / Agache, Ioana / Bavbek, Sevim / Bossios, Apostolos / Casper, Ingrid / Chan, Susan / Chatzipetrou, Alexia / Vogelberg, Christian / Firinu, Davide / Kauppi, Paula / Kolios, Antonios /

Allergol Select

Abstract: BACKGROUND: Since the beginning of the COVID-19 pandemic, the treatment of patients with allergic and atopy-associated diseases has faced major challenges. Recommendations for "social distancing" and the fear of patients becoming infected during a visit ... ...

Abstract	BACKGROUND: Since the beginning of the COVID-19 pandemic, the treatment of patients with allergic and atopy-associated diseases has faced major challenges. Recommendations for "social distancing" and the fear of patients becoming infected during a visit to a medical facility have led to a drastic decrease in personal doctor-patient contacts. This affects both acute care and treatment of the chronically ill. The immune response after SARS-CoV-2 infection is so far only insufficiently understood and could be altered in a favorable or unfavorable way by therapy with monoclonal antibodies. There is currently no evidence for an increased risk of a severe COVID-19 course in allergic patients. Many patients are under ongoing therapy with biologicals that inhibit type 2 immune responses via various mechanisms. There is uncertainty about possible immunological interactions and potential risks of these biologicals in the case of an infection with SARS-CoV-2. MATERIALS AND METHODS: A selective literature search was carried out in PubMed, Livivo, and the internet to cover the past 10 years (May 2010 - April 2020). Additionally, the current German-language publications were analyzed. Based on these data, the present position paper provides recommendations for the biological treatment of patients with allergic and atopy-associated diseases during the COVID-19 pandemic. RESULTS: In order to maintain in-office consultation services, a safe treatment environment must be created that is adapted to the pandemic situation. To date, there is a lack of reliable study data on the care for patients with complex respiratory, atopic, and allergic diseases in times of an imminent infection risk from SARS-CoV-2. Type-2-dominant immune reactions, as they are frequently seen in allergic patients, could influence various phases of COVID-19, e.g., by slowing down the immune reactions. Theoretically, this could have an unfavorable effect in the early phase of a SARS-Cov-2 infection, but also a positive effect during a cytokine storm in the later phase of severe courses. However, since there is currently no evidence for this, all data from patients treated with a biological directed against type 2 immune reactions who develop COVID-19 should be collected in registries, and their disease courses documented in order to be able to provide experience-based instructions in the future. CONCLUSION: The use of biologicals for the treatment of bronchial asthma, atopic dermatitis, chronic rhinosinusitis with nasal polyps, and spontaneous urticaria should be continued as usual in patients without suspected infection or proven SARS-CoV-2 infection. If available, it is recommended to prefer a formulation for self-application and to offer telemedical monitoring. Treatment should aim at the best possible control of difficult-to-control allergic and atopic diseases using adequate rescue and add-on therapy and should avoid the need for systemic glucocorticosteroids. If SARS-CoV-2 infection is proven or reasonably suspected, the therapy should be determined by weighing the benefits and risks individually for the patient in question, and the patient should be involved in the decision-making. It should be kept in mind that the potential effects of biologicals on the immune response in COVID-19 are currently not known. Telemedical offers are particularly desirable for the acute consultation needs of suitable patients.
Keywords	covid19
Publisher	WHO
Document type	Article
Note	WHO #Covidence: #761024
Database	COVID19

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾

Article ; Online: Use of biologicals in allergic and type-2 inflammatory diseases during the current COVID-19 pandemic: Position paper of Ärzteverband Deutscher Allergologen (AeDA)

Kothari, Akash / Matucci, Andrea / Palomares, Oscar / Szépfalusi, Zsolt / Pohl, Wolfgang / Hötzenecker, Wolfram / Rosenkranz, Alexander R / Bergmann, Karl-Christian / Bieber, Thomas / Buhl, Roland / Buters, Jeroen / Darsow, Ulf / Keil, Thomas / Kleine-Tebbe, Jörg / Lau, Susanne / Maurer, Marcus / Merk, Hans / Mösges, Ralph / Saloga, Joachim / Staubach, Petra / Jappe, Uta / Rabe, Klaus F / Rabe, Uta / Vogelmeier, Claus / Biedermann, Tilo / Jung, Kirsten / Schlenter, Wolfgang / Ring, Johannes / Chaker, Adam / Wehrmann, Wolfgang / Becker, Sven / Freudelsperger, Laura / Mülleneisen, Norbert / Nemat, Katja / Czech, Wolfgang / Wrede, Holger / Brehler, Randolf / Fuchs, Thomas / Tomazic, Peter-Valentin / Aberer, Werner / Fink-Wagner, Antje-Henriette / Horak, Fritz / Wöhrl, Stefan / Niederberger-Leppin, Verena / Pali-Schöll, Isabella / Roller-Wirnsberger, Regina / Spranger, Otto / Valenta, Rudolf / Akdis, Mübecell / Matricardi, Paolo M / Spertini, François / Khaltaev, Nicolai / Michel, Jean-Pierre / Nicod, Larent / Schmid-Grendelmeier, Peter / Idzko, Marco / Hamelmann, Eckard / Jakob, Thilo / Werfel, Thomas / Wagenmann, Martin / Taube, Christian / Jensen-Jarolim, Erika / Korn, Stephanie / Hentges, Francois / Schwarze, Jürgen / O Mahony, Liam / Knol, Edward F / Del Giacco, Stefano / Chivato Pérez, Tomás / Bousquet, Jean / Bedbrook, Anna / Zuberbier, Torsten / Akdis, Cezmi / Jutel, Marek

Allergologie select

2020 Volume 4, Page(s) 53–68

Abstract: Background: Since the beginning of the COVID-19 pandemic, the treatment of patients with allergic and atopy-associated diseases has faced major challenges. Recommendations for "social distancing" and the fear of patients becoming infected during a visit ...

Abstract	Background: Since the beginning of the COVID-19 pandemic, the treatment of patients with allergic and atopy-associated diseases has faced major challenges. Recommendations for "social distancing" and the fear of patients becoming infected during a visit to a medical facility have led to a drastic decrease in personal doctor-patient contacts. This affects both acute care and treatment of the chronically ill. The immune response after SARS-CoV-2 infection is so far only insufficiently understood and could be altered in a favorable or unfavorable way by therapy with monoclonal antibodies. There is currently no evidence for an increased risk of a severe COVID-19 course in allergic patients. Many patients are under ongoing therapy with biologicals that inhibit type 2 immune responses via various mechanisms. There is uncertainty about possible immunological interactions and potential risks of these biologicals in the case of an infection with SARS-CoV-2. Materials and methods: A selective literature search was carried out in PubMed, Livivo, and the internet to cover the past 10 years (May 2010 - April 2020). Additionally, the current German-language publications were analyzed. Based on these data, the present position paper provides recommendations for the biological treatment of patients with allergic and atopy-associated diseases during the COVID-19 pandemic. Results: In order to maintain in-office consultation services, a safe treatment environment must be created that is adapted to the pandemic situation. To date, there is a lack of reliable study data on the care for patients with complex respiratory, atopic, and allergic diseases in times of an imminent infection risk from SARS-CoV-2. Type-2-dominant immune reactions, as they are frequently seen in allergic patients, could influence various phases of COVID-19, e.g., by slowing down the immune reactions. Theoretically, this could have an unfavorable effect in the early phase of a SARS-Cov-2 infection, but also a positive effect during a cytokine storm in the later phase of severe courses. However, since there is currently no evidence for this, all data from patients treated with a biological directed against type 2 immune reactions who develop COVID-19 should be collected in registries, and their disease courses documented in order to be able to provide experience-based instructions in the future. Conclusion: The use of biologicals for the treatment of bronchial asthma, atopic dermatitis, chronic rhinosinusitis with nasal polyps, and spontaneous urticaria should be continued as usual in patients without suspected infection or proven SARS-CoV-2 infection. If available, it is recommended to prefer a formulation for self-application and to offer telemedical monitoring. Treatment should aim at the best possible control of difficult-to-control allergic and atopic diseases using adequate rescue and add-on therapy and should avoid the need for systemic glucocorticosteroids. If SARS-CoV-2 infection is proven or reasonably suspected, the therapy should be determined by weighing the benefits and risks individually for the patient in question, and the patient should be involved in the decision-making. It should be kept in mind that the potential effects of biologicals on the immune response in COVID-19 are currently not known. Telemedical offers are particularly desirable for the acute consultation needs of suitable patients.
Keywords	covid19
Language	English
Publishing date	2020-09-07
Publishing country	Germany
Document type	Journal Article
ZDB-ID	2893503-2
ISSN	2512-8957 ; 2512-8957
ISSN (online)	2512-8957
ISSN	2512-8957
DOI	10.5414/ALX02166E
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: [No title information]

Kothari, Akash / Matucci, Andrea / Palomares, Oscar / Szépfalusi, Zsolt / Pohl, Wolfgang / Hötzenecker, Wolfram / Rosenkranz, Alexander / Bergmann, Karl-Christian / Bieber, Thomas / Buhl, Roland / Buters, Jeroen / Darsow, Ulf / Keil, Thomas / Kleine-Tebbe, Jörg / Lau, Susanne / Maurer, Marcus / Merk, Hans / Mösges, Ralph / Saloga, Joachim / Staubach, Petra / Jappe, Uta / Rabe, Claus / Rabe, Uta / Vogelmeier, Claus / Biedermann, Tilo / Jung, Kirsten / Schlenter, Wolfgang / Ring, Johannes / Chaker, Adam / Wehrmann, Wolfgang / Becker, Sven / Freudelsperger, Laura / Mülleneisen, Norbert / Nemat, Katja / Czech, Wolfgang / Wrede, Holger / Brehler, Randolf / Fuchs, Thomas / Tomazic, Peter-Valentin / Aberer, Werner / Fink Wagner, Antje / Horak, Fritz / Wöhrl, Stefan / Niederberger-Leppin, Verena / Pali-Schöll, Isabella / Roller-Wirnsberger, Regina / Spranger, Otto / Valenta, Rudolf / Akdis, Mübecell / Matricardi, Paolo M / Spertini, François / Khaltaev, Nikolai / Michel, Jean-Pierre / Nicod, Larent / Schmid-Grendelmeier, Peter / Idzko, Marco / Hamelmann, Eckard / Jakob, Thilo / Werfel, Thomas / Wagenmann, Martin / Taube, Christian / Jensen-Jarolim, Erika / Korn, Stephanie / Hentges, Francois / Schwarze, Jürgen / O Mahony, Liam / Knol, Edward / Del Giacco, Stefano / Chivato, Tomás / Bousquet, Jean / Zuberbier, Torsten / Akdis, Cezmi / Jutel, Marek

Allergo Journal : interdisziplinare Zeitschrift fur Allergologie und Umweltmedizin : Organ der Deutschen Gesellschaft fur Allergie- und Immunitatsforschung

2020 Volume 29, Issue 4, Page(s) 14–27

Title translation	Anwendung von Biologika bei allergischen und Typ-2-entzündlichen Erkrankungen in der aktuellen Covid-19-Pandemie
Keywords	covid19
Language	German
Publishing date	2020-06-24
Publishing country	Germany
Document type	Journal Article ; Review
ZDB-ID	1136943-7
ISSN	0941-8849
ISSN	0941-8849
DOI	10.1007/s15007-020-2553-y
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 3566: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Anwendung von Biologika bei allergischen und Typ-2-entzündlichen Erkrankungen in der aktuellen Covid-19-Pandemie(a, b, c): Positionspapier des Ärzteverbands Deutscher Allergologen (AeDA)A, der Deutschen Gesellschaft für Allergologie und klinische Immunologie (DGAKI)B, der Gesellschaft für Pädiatrische Allergologie und Umweltmedizin (GPA)C, der Österreichischen Gesellschaft für Allergologie und Immunologie (ÖGAI)D, der Luxemburgischen Gesellschaft für Allergologie und Immunologie (LGAI)E, der Österreichischen Gesellschaft für Pneumologie (ÖGP)F in Kooperation mit der deutschen, österreichischen, und schweizerischen ARIA-GruppeG und der Europäischen Akademie für Allergologie und Klinische Immunologie (EAACI)H

Kothari, Akash / Matucci, Andrea / Palomares, Oscar / Szépfalusi, Zsolt / Pohl, Wolfgang / Hötzenecker, Wolfram / Rosenkranz, Alexander / Bergmann, Karl-Christian / Bieber, Thomas / Buhl, Roland / Buters, Jeroen / Darsow, Ulf / Keil, Thomas / Kleine-Tebbe, Jörg / Lau, Susanne / Maurer, Marcus / Merk, Hans / Mösges, Ralph / Saloga, Joachim / Staubach, Petra / Jappe, Uta / Rabe, Claus / Rabe, Uta / Vogelmeier, Claus / Biedermann, Tilo / Jung, Kirsten / Schlenter, Wolfgang / Ring, Johannes / Chaker, Adam / Wehrmann, Wolfgang / Becker, Sven / Freudelsperger, Laura / Mülleneisen, Norbert / Nemat, Katja / Czech, Wolfgang / Wrede, Holger / Brehler, Randolf / Fuchs, Thomas / Tomazic, Peter-Valentin / Aberer, Werner / Fink Wagner, Antje / Horak, Fritz / Wöhrl, Stefan / Niederberger-Leppin, Verena / Pali-Schöll, Isabella / Roller-Wirnsberger, Regina / Spranger, Otto / Valenta, Rudolf / Akdis, Mübecell / Matricardi, Paolo M. / Spertini, François / Khaltaev, Nikolai / Michel, Jean-Pierre / Nicod, Larent / Schmid-Grendelmeier, Peter / Idzko, Marco / Hamelmann, Eckard / Jakob, Thilo / Werfel, Thomas / Wagenmann, Martin / Taube, Christian / Jensen-Jarolim, Erika / Korn, Stephanie / Hentges, Francois / Schwarze, Jürgen / O´Mahony, Liam / Knol, Edward / del Giacco, Stefano / Chivato, Tomás / Bousquet, Jean / Zuberbier, Torsten / Akdis, Cezmi / Jutel, Marek

Allergo J

Keywords	covid19
Publisher	PMC
Document type	Article ; Online
DOI	10.1007/s15007-020-2553-y
Database	COVID19

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Kategorien

Inter-library loan at ZB MED

Full text online

More links

Kategorien

Inter-library loan at ZB MED

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Kategorien

Inter-library loan at ZB MED